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Haem is a structural component of numerous cellular proteins which contributes
significantly to iron metabolic processes in mammals but its toxicity demands that cellular
levels must be tightly regulated. Breast Cancer Resistance Protein (BCRP/ABCG2), an
ATP Binding Cassette G-member protein has been shown to possess porphyrin/haem
efflux function. The current study evaluated the expression and regulation of Abcg2 mRNA
and protein levels in mouse tissues involved in erythropoiesis. Abcg2 mRNA expression
was enhanced in bone marrow hemopoietic progenitor cells from mice that were
treated with phenylhydrazine (PHZ). Abcg2 mRNA expression was increased particularly
in the extramedullary haematopoietic tissues from all the mice models with enhanced
erythropoiesis. Haem oxygenase (ho1) levels tended to increase in the liver of mice with
enhanced erythropoiesis and gene expression patterns differed from those observed in
the spleen. Efflux of haem biosynthetic metabolites might be dependent on the relative
abundance of Abcg2 or ho1 during erythropoiesis. Abcg2 appears to act principally as a
safety valve regulating porphyrin levels during the early stages of erythropoiesis and its
role in systemic haem metabolism and erythrophagocytosis, in particular, awaits further
clarification.
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INTRODUCTION
Iron turnover in mammals is largely explained by the pro-
duction (biosynthesis) and breakdown (biodegradation) of
erythrocytes. Consequently iron fluxes during erythropoiesis and
erythrophagocytosis must be balanced and this is mainly achieved
by influences of hepcidin in the maintenance of iron home-
ostasis. Three essential substrates, iron, porphyrin, and haem as
well as their combination, are essential for erythropoiesis but
are potentially toxic if allowed to accumulate. Iron, haem, and
photosensitized porphyrin are pro-oxidants and they can cause
damage to DNA, proteins and cell membrane systems. Availability
of iron, a limiting nutrient, and the de novo synthesis of haem
and porphyrin are therefore strictly coordinated and channeled
to avert the accumulation of excess toxic metabolites. Recently
the identification of two haem efflux proteins, Breast Cancer
Resistant Protein (BCRP or ABCG2) and Feline Leukaemia Virus
C Receptor (FLVCR) has defined importantmechanisms that pro-
tect cells and tissues against noxious free haem (Quigley et al.,
2004; Krishnamurthy and Schuetz, 2005a). Abcg2 is a half ATP-
Binding Cassette (ABC) G-member transporter with a nucleotide
binding domain (NBD) at its amino terminus and a transmem-
brane domain at its carboxyl end (Krishnamurthy and Schuetz,
2006). It functions conventionally as a plasma membrane protein
extruding endogenous and exogenous toxic xenobiotics from the
intestine, liver, placenta, and the blood/brain barrier. This trans-
porter, in some instances, confers resistance to anticancer drugs.
The broad substrate spectrum of abcg2 are porphyrin metabolites
(Suzinges-Mandon et al., 2010). Specifically, Abcg2 was shown
as a porphyrin efflux protein which functions to rid erythroid
cells of excess porphyrins particularly under hypoxic conditions
(Krishnamurthy et al., 2004) and thereby protects haematopoietic
cells from the potential toxicity of excess free porphyrin com-
pounds. As hypoxia could vary in magnitude depending on the
duration and the type of anaemia, the detoxification function of
abcg2 might be pertinent in the various other tissues that handle
large quantities of haem and its degradation products e.g., liver.
At the cellular level, haem oxygenase 1 (ho1) catalyses the
rate limiting step in the degradation of haem into iron, car-
bon monoxide, and biliverdin, which is reduced by biliverdin
reductase to bilirubin. These by-products also constitute potential
substrates for abcg2, and have recently been shown to have antiox-
idant, anti-inflammatory, and cytoprotective functions (Bilban
et al., 2008; Soares and Bach, 2009). Excess haem is presumed
to be channeled into the lysosome for catabolism or might be
effluxed into circulation where it binds to hemopexin (Tolosano
et al., 2010). Haem and its metabolites may be substantially
and strategically trafficked or otherwise degraded in a coordi-
nated and regulated manner under different modulators of iron
metabolism. Moreover, abcg2 might play a vital role in the trans-
port of haem and porphyrin compounds during erythropoiesis.
This study investigates the expression and regulation of abcg2 and
ho1 in tissues of mice with enhanced erythropoiesis.
www.frontiersin.org June 2014 | Volume 5 | Article 135 | 1
Latunde-Dada et al. ABCG2 expression in enhanced erythropoiesis models
MATERIALS AND METHODS
ANIMALS AND TISSUE COLLECTION
CD1 mice were used for all experiments except the hypotrans-
ferrinaemic (Hpx) mice that are of Balb/c background. Mice
were placed in a hypobaric chamber at 0.5 atm for 72 h to effect
hypoxia. Controls were kept at room air pressure. Dietary iron
deficiency was induced by feeding 4-week old CD1 male mice
with a low-iron diet (Formula TD. 80396, elemental iron concen-
tration: 3–6mg/kg or control diet containing 48mg/kg iron, TD.
80394; Harlan-Teklad; Madison, WI, USA) for 3 weeks. Enhanced
erythrocyte turnover was induced by intraperitoneal injections
of neutralized phenylhydrazine (PHZ) at 60mg/kg body weight;
(Sigma-Aldrich, UK) on 2 consecutive days. All mice were main-
tained on standard commercial diet (Rodent Maintenance diet;
RM1, Special Diet Services, UK) feed and water ad libitum.
Mice were sacrificed after anaesthesia and neck dislocation, after
which tissues were collected. Femurs were excised and flushed
with Dulbecco’s minimum essential medium (DMEM; Sigma-
Aldrich, UK), to collect the hemopoeitic progenitor cells from the
bone marrow of control and PHZ-treated CD1 mice. All proce-
dures were approved and conducted in accordance with the UK.
Animals (Scientific Procedures Act, 1986).
CELL CULTURE
RT-PCR
Total RNA was extracted from tissue samples using Trizol
reagent (Invitrogen, UK) according to manufacturer’s instruc-
tions. Quantitative RT-PCR was carried out using an ABI Prism
7000 detection system in a two-step protocol with SYBR Green
(ABI, Life Technologies, UK). The efficacy of the amplification
was confirmed by a melting curve analysis and gel electrophoresis
to confirm the presence of a single product.
Quantitative measurement of each gene was derived from a
standard curve constructed from known amounts of PCR prod-
uct. The results were calculated by the Ct method that expresses
the difference in threshold for the target gene relative to that
of 18S RNA. Sequences of primers used, forward, and reverse,
respectively, are as follow:
Mouse abcg2 5′-TCGCAGAAGGAGATGTGTTGAG-3′
5′-CCAGAATAGCATTAAGGCCAGG-3′
Mouse tfr1, 5′-CATGGTGACCATAGTGCACTCA-3′
5′-AGCATGGACCAGTTTACCAGAA-3′
Mouse ho1 5′-CAAGGAGGTACACATCCAAGCC-3′
5′-TACAAGGAAGCCATCACCAGCT-3′
Mouse 18s 5′-GAATTCCCAGTAAGTGCGGG-3′
5′-GGGCAGGGACTTAATCAACG-3′
Human 18s 5′-AACTTTCGATGGTAGTCGCCG-3′
5′-CCTTGGATGTGGTAGCCGTTT-3′
Western blot analysis
Spleen tissue was homogenized (in a buffer containing 50mM
mannitol, 2mM Hepes, 0·5mM PMSF and pH 7·2) with an
Ultra Turrax (IKA, Staufen, Germany) homogenizer in (3 ×
30 s pulses at full speed). The homogenate was centrifuged at
1500 g for 5min and the supernatant was centrifuged for 1 h
at 15,000 g to obtain the crude membrane fraction. Protein
concentration was determined using Bio-Rad reagents (Bio-Rad,
Laboratories, Hercules, CA, USA). Fifty (50) μg of membrane
extracts were loaded onto a 12% gel in a SDS-PAGE. The proteins
separated were then transferred to Hybond ECL-nitrocellulose
membrane (Amersham Biosciences, Bucks, UK) using a Bio-Rad
semidry transfer apparatus (Trans-BlotR SD Semi-Dry Transfer
Cell; Bio-Rad, UK). Membranes were blocked with 5% milk
for 1 h and probed with ABCG2 BXP-53 monoclonal (Santa
Cruz Biotechnology, USA), and, β-actin (Sigma, UK) antibod-
ies diluted in 0.01% milk in TBS. Cross-reactivity was observed
with peroxidase-linked anti-IgG by using SuperSignal West Pico
(Thermo Scientific, USA).
Statistical analysis
All values are expressed as mean ± s.e.m. Statistical differ-
ences between means were calculated with Microsoft Excel 6.0
(Microsoft, Seattle, WA, USA) by using the Student t-test correct-
ing for differences in sample variance. When multiple compar-
isons were necessary, One-Way analysis of variance (ANOVA) was
performed using SPSS 14 (SPSS Inc, Chicago, US) with Tukey’s
post-hoc test.
RESULTS
Abcg2 and tfr1 mRNA expression were enhanced in bone marrow
cells from mice treated with PHZ (Figure 1). Increased erythro-
poietic activity, which typifies Hpx, PHZ-treated, hypoxic, and
iron-deficient mice, was associated with significant increases in
abcg2 mRNA expression in the spleen tissues from the mice
(Figure 2). While changes in ho1 mRNA expression in spleen tis-
sues varied widely with the mice models (Figure 3A), hepatic ho1
mRNA was induced significantly in Hpx and PHZ-treated mice
(Figure 3B) instead. Enhancement of abcg2 protein expression
in the spleen from mice with enhanced erythropoiesis correlated
with the pattern of increased mRNA expression (Figures 4A,B).
FIGURE 1 | Abcg2 and TfR1 mRNA levels in bone marrow precursor
cells of CD1 mice. Erythropoiesis was induced with phenylhydrazine (PHZ)
administration (60mg/kg) over 2 days. Relative mRNA expression was
obtained by normalizing mRNA levels to 18S mRNA. Analysis by Students’
T -test showed significant effects of abcg2 (P < 0.01), and TfR1 (P < 0.005)
over the control samples.
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FIGURE 2 | Quantitative Real-Time PCR of Abcg2 mRNA levels in
spleen of mouse models with enhanced erythropoiesis. Abcg2 mRNA
levels in the spleen of Hpx, PHZ-treated, hypoxic, and iron-deficient mice.
Data are mean ± s.e.m. of four observations in each group and are
expressed as a ratio of 18S mRNA in arbitrary units. Analysis by Students’
T -test showed significant effects of abcg2 mRNA in Hpx (P < 0.01), PHZ
(P < 0.01), hypoxia (P < 0.05), and iron-deficient spleen tissues, (P < 0.05)
over the control samples.
There was a slight, but observable, increase in ho1 protein levels
in spleen tissues from PHZ-treated, hypoxic, and iron-deficient
mice (Figures 4A,C).
Abcg2 mRNA expression showed decreases in mouse model
with enhanced erythropoiesis in kidney tissues (Figure 5A)
but the response were not significantly different. Ho1 mRNA
expression was significantly enhanced in kidney tissues from
Hpx and iron-deficient mouse models (Figure 5B). Only modest
increases in ho1 mRNA expression levels were observed in kidney
tissues from PHZ-treated and hypoxic mouse models.
DISCUSSION
Abcg2, an efflux protein with broad substrate specificity, is char-
acteristically localized and expressed in epithelial membranes
of barrier tissues such as the intestine, placenta, liver and the
brain. The regulation of cellular haem and porphyrin levels by
abcg2 plays a pivotal physiological function in erythropoiesis and
iron metabolism in mammals. Abcg2 mRNA expression coincides
with enhanced stimulation of haemoglobin biosynthesis (Zhou
et al., 2005), during differentiation between BFU-E and CFU-E.
Globin transcription and iron uptake are enhanced and haem
concentration is critical for the initiation of haemoglobin syn-
thesis (Krishnamurthy and Schuetz, 2005a). This fact might be
the reason for the increase in abcg2 mRNA expression in the
hemopoeitic precursor cells in mice that were administered with
PHZ (Figure 1). As haemoglobinization increases with the pro-
gression of erythropoiesis, proerythrocytes presumably express
low levels of ho1 and are highly sensitive to low levels of cytosolic
haem. Abcg2 prevents porphyrin toxicity especially under hypoxic
conditions, during the mid to the distal stages of erythropoiesis.
Flvcr1 also effluxes excess haem during erythropoiesis and ery-
throphagocytosis (Keel et al., 2008; Chiabrando et al., 2012; Byon
et al., 2013). Typical of promoters devoid of the TATA box, abcg2
promoter has multiple transcription sites (Lin et al., 2001). Zong
et al. (2006) showedmultiple transcription start sites from several
FIGURE 3 | Quantitative Real-Time PCR of Ho1 mRNA levels in spleen
and liver of mouse models with enhanced erythropoiesis. (A) Ho1
mRNA levels in the spleen of Hpx, PHZ-treated, hypoxic, and iron deficient
mice. Analysis by Students’ T -test showed significant effects of Ho1 only in
iron-deficient spleen tissues, (P < 0.01) over the control samples. (B) Ho1
mRNA expression in the liver of Hpx, PHZ-treated, hypoxic, and iron
deficient mice. Analysis by Students’ T -test showed significant effects of
Ho-1 mRNA in Hpx (P < 0.05), and PHZ liver tissues, (P < 0.01) over the
control samples. Data are mean ± s.e.m. of four observations in each
group and are expressed as a ratio of 18S mRNA in arbitrary units.
leader exons in abcg2 gene. Moreover, these promoter regions are
enriched with several transcription factors binding sites (Ishikawa
et al., 2013). Furthermore, abcg2 promoter is regulated by tis-
sue specific transcription factors such as GATA 2 (Minegishi
et al., 1998). Consequently, abcg2 gene regulation is varied and
multifarious in tissues and during diverse physiological processes.
Similarly, abcg2 mRNA expression (Figure 2) and protein lev-
els (Figures 4A,B) were consistently up-regulated in the spleen
of mice with enhanced erythropoiesis. Abcg2 and, more recently
flvcr1 (Vinchi et al., 2014), have been reported to regulate haem
levels in cells during erythropoiesis. Evidence from literature
suggests a reciprocal pattern in flvcr vs. abcg2 expression as dif-
ferentiation progresses (Keller et al., 2006). Flvcr null mice are
non-viable and this confirms a lack of functional overlap with
abcg2. Flvcr is presumed to efflux haem into circulation from
macrophages (Keel et al., 2008) and possibly functions specifi-
cally during erythrophagocytosis. The latter report implied that
a proportion of haem from phagocytosed, senescent red blood
cells in macrophages is not degraded but effluxed into circula-
tion by flvcr. This haem “cargo” could subsequently be bound
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FIGURE 4 | Western blot analysis of Abcg2 protein and Ho1 levels in
the spleen samples from Hpx, PHZ-treated, hypoxic and iron-deficient
mice. (A) Abcg2 protein levels in mouse spleen samples that were
homogenized and subjected to Western blotting as described under
methods. (B) Abcg2 protein levels in the spleen tissues. Densitometries of
the bands (upper) were quantified with Image J software and data were
normalized with the levels of β-actin protein in the samples. (C) Ho1
protein levels in the spleen tissues from mice. Densitometric data are
presented as the mean ± s.e.m. of four experiments in each group.
∗P < 0.05, ∗∗P < 0.001.
by hemopexin for delivery to the liver. It has recently been
shown that hemopexin is obligatory to the functional haem
efflux capability of flvcr (Yang et al., 2010). Flvcr, in contrast to
some other members of the major facilitator superfamily, is a
unidirectional, vectorial transporter.
Similarly, splenic expression of abcg2 might also correlate
with its role in detoxification processes. Haem, apart from
being endogenously synthesized ubiquitously by erythroid and
non-erythroid tissues, is also derived from haemolysis and
haemorrhage (Reeder et al., 2002). While PHZ-treated mice are
characterized by increased haemolysis and destruction of red
blood cells, ho1 mRNA expression was significantly enhanced in
the liver rather than in the spleen of these mice (Figures 3A,B).
The reasons for variation in the basal levels of ho1 in the different
mice models used in this study remain, however, both puzzling
and unclear. The regulation of haem thus favors the depletion
of unbound forms (Vinchi et al., 2008) to ameliorate toxicity in
cellular and subcellular loci of visceral and peripheral tissues. It
is well documented that ho1 expression is highly inducible in
the presence of haem (Schwarzer et al., 1999; Desbuards et al.,
2009). Consequently, intracellular and extracellular trafficking
of haem is regulated to molecular channeling in organelles and
ensures detoxification as necessary. Ho1 mRNA was generally
enhanced in the kidney tissues from mice in the current study
(Figure 5) although kidney abcg2 mRNA levels were not signifi-
cantly different. The kidney is important in iron metabolism for
the biogenesis and biodegradation of haem. The former is by a
regulatory feedback loop of erythropoietin production and the
latter by the glomerullar filtration of haem bymegalin and cubilin
receptors (Gburek et al., 2002, 2003). Consequently, Abcg2 might
not be involved in the efflux of haem/porphyrin in the kidney
as it does in erythroid progenitor cells. Perhaps megalin and
cubilin function in concert and are complimentarily with ho1 to
exude the resultant porphyrin breakdown products of haem: this
remains an unanswered question.
In conclusion, abcg2, effluxes excess porphyrin metabolites
and possibly excess haem during erythropoiesis particularly
under hypoxic conditions. Egress and detoxification of excess
porphyrin/haem by abcg2 and flvcr to maintain cellular home-
ostasis is presumably complemented by ho1 expression during the
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FIGURE 5 | Quantitative Real-Time PCR of Abcg2 and Ho1 mRNA
levels in the kidney tissue samples from mouse models with
enhanced erythropoiesis. (A) Abcg2 mRNA levels in the kidney of Hpx,
PHZ-treated, hypoxic, and iron-deficient mice. Data are mean ± s.e.m. of
four observations in each group and are expressed as a ratio of 18S mRNA
in arbitrary units. (B) Ho1 mRNA levels in the kidney of Hpx, PHZ-treated,
hypoxic, and iron-deficient mice. Data are mean ± s.e.m. of four
observations in each group and are expressed as a ratio of 18S mRNA in
arbitrary units. Analysis by Students’ T -test showed significant effects of
HO-1 mRNA levels in Hpx (P < 0.01), and iron-deficient spleen tissues,
(P < 0.01) over the control samples.
early stages of erythropoiesis. Consequently, abgc2 mRNA levels
are stimulated during enhanced erythropoiesis in extramedullary
haematopoietic splenic and liver tissues of Hpx, PHZ-treated,
hypoxic, and iron-deficient mice. However, abcg2 expression is
low in the kidney, and in tissues of this organ ho1 degradation
of haem might predominate. Tissue-specific expression of haem
influx/efflux proteins and haem catabolism by ho1 must be crit-
ically balanced to maintain optimal levels of haem for metabolic
processes.
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